Phaseline

Targets › PSMA

PSMA (Glutamate carboxypeptidase 2): drug programs, companies and trials

31 programs from 27 companies in 42 trials: 25 Phase 1, 12 Phase 2, 4 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.

Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. (UniProt, Q04609)

Open in Phaseline: the race on PSMA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lantheus Medical ImagingPiflufolastat F 18
Prostate-specific membrane antigen (PSMA)-targeting PET imaging agent
PSMAPhase 4Prostate Cancer–
Clarity Pharmaceuticals64Cu-SAR-bisPSMA
64Cu-labeled anti-PSMA bisPSMA antibody for imaging
PSMA, FOLH1Phase 3Prostate Cancer; Prostatic Neoplasms, Castration-ResistantDec 2026
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company[Lu-177]-PNT2002
Lutetium-177 labeled PSMA targeted radioligand therapy
PSMAPhase 3Metastatic Castration-Resistant Prostate CancerMar 2028
Curium US177Lu-PSMA-I&T
Lutetium-177 labeled PSMA-targeting radioligand therapy
PSMAPhase 3Metastasis From Malignant Tumor of Prostate; Prostate CancerFeb 2029
Fusion PharmaceuticalsFPI-2265
Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy)
PSMA, FOLH1Phase 2Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate CancerDec 2026
Peter MacCallum Cancer Centre, Australia177Lu-PSMA
PSMA-targeting radiopharmaceutical (lutetium-177 beta emitter)
PSMAPhase 2Oligometastatic Prostate CancerMay 2027
Weill Medical College of Cornell University177Lu-J591
PSMA-targeted radioimmunotherapy; humanized monoclonal antibody against prostate-specific
PSMAPhase 2Prostate CancerJun 2027
First Affiliated Hospital of Fujian Medical University177Lu-P17-088
PSMA-targeted radioligand (lutetium-177 conjugate with albumin-binding property)
PSMAPhase 2Prostate CancerJun 2027
National Cancer Institute (NCI)18F-DCFPyL
High affinity small molecule inhibitor of PSMA for PET imaging
PSMAPhase 2Prostate Cancer; Metastatic Prostate Cancer; Localized Prostate Cancer; Prostatic Neoplasms …Nov 2027
Columbia University[18F]DCFPyL
PSMA-targeting PET imaging agent
PSMAPhase 2Metastatic Prostate Cancer–
Weill Medical College of Cornell University225Ac-J591
Alpha-emitter radiopharmaceutical; Actinium-225 conjugated to anti-PSMA antibody J591
PSMA, FOLH1Phase 1Prostate CancerDec 2026
Jonsson Comprehensive Cancer Center177Lu-PSMA
Lutetium-177 labeled PSMA-targeting radioligand
PSMAPhase 1Castration-Resistant Prostate CarcinomaDec 2026
C Ray TherapeuticsTRDC002
PSMA-targeting radiotracer (64Cu-labeled)
PSMAPhase 1Prostate CancerDec 2026
Xiaorong Sun[225Ac]Ac-PSMA-XT
Alpha-emitting radiopharmaceutical targeting PSMA
PSMAPhase 1Metastatic Castration-Resistant Prostate Cancer PatientsDec 2026
M.D. Anderson Cancer CenterPiflufolastat F18
PSMA-targeted PET imaging agent
PSMAPhase 1Pancreatic CancerFeb 2027
Beijing BiotechETB-DualNK-01
Dual-target anti-PSMA/PSCA CAR-NK cells
PSMA, PSCAPhase 1Metastatic Castration-resistant Prostate CancerMar 2027
Jinming Zhang[177Lu]Lu-PSMA-XT
Radioligand therapy delivering beta-particle radiation to PSMA-expressing cells
PSMAPhase 1mCRPCApr 2027
Chunjing YuLu 177-PSMA-3D1015 Injection
PSMA-targeted radioligand therapy (lutetium-177 labeled)
PSMAPhase 1Metastatic Castration-resistant Prostate Cancer, mCRPCJun 2027
Eli Lilly[Ac-225]-PSMA-62
Actinium-225 labeled anti-PSMA targeted alpha particle therapy
PSMAPhase 1Prostate CancerSep 2027
ARTBIOAB001
Pb-212 PSMA-targeted alpha-emitting radioligand
PSMAPhase 1Prostate Cancer (CRPC)Nov 2027
C Ray TherapeuticsTRC003
225Ac-labeled PSMA-targeted alpha particle therapy (targeted alpha therapy)
PSMAPhase 1Prostate CancerDec 2027
Inovio PharmaceuticalsINO-5401
DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens
WT1, PSMA, HGNCPhase 1GlioblastomaDec 2027
Blue Earth TherapeuticsLutetium (177Lu) rhPSMA-10.1 Injection
177Lu-labeled recombinant human PSMA-targeting radiopharmaceutical
PSMAPhase 1Prostate CancerMar 2028
University Hospital, Basel, Switzerland161Tb-SibuDAB
PSMA-targeted radionuclide therapy with terbium-161
PSMAPhase 1Castration-resistant Prostate CancerJun 2028
Peter MacCallum Cancer Centre, Australia[161Tb]Tb-PSMA-I&T
Prostate-specific membrane antigen (PSMA) targeted radioligand therapy using terbium-161
PSMAPhase 1Prostate CancerSep 2028
Bayer225Ac-PSMA-Trillium (BAY3563254)
PSMA-targeting alpha-emitting radioligand (actinium-225)
PSMAPhase 1Advanced Metastatic Castration-resistant Prostate CancerNov 2028
Yunhe Pharmaceutical (Tianjin) Co., LtdINR102 injection
Lutetium-177-labeled radiopharmaceutical targeting PSMA
PSMAPhase 1Prostate CancerJun 2029
Norroy Bioscience177Lu-NYM032 injection
PSMA-targeting radioligand therapeutic agent
PSMAPhase 1Metastatic Castration-resistant Prostate Cancer–
Clarity Pharmaceuticals67Cu-SAR-bisPSMA
67Cu-labeled anti-PSMA bisPSMA antibody for therapeutic targeting
PSMAPhase 1Prostatic Neoplasms, Castration-Resistant–
Nova TherapeuticsCART-PSMA cells
CAR-T cell therapy targeting PSMA (prostate-specific membrane antigen)
PSMAPhase 1Prostate Cancer–
Sinotau Pharmaceutical GroupFlotufolastat F-18 Injection
PSMA-targeted PET imaging tracer
PSMAPhase 1Prostate Cancer–

Conditions

Prostate Cancer (18) Metastatic Castration-resistant Prostate Cancer (4) Metastatic Prostate Cancer (2) Prostatic Neoplasms, Castration-Resistant (2) Localized Prostate Cancer (1) Prostatic Neoplasms (1) Prostate Neoplasms (1) Oligometastatic Prostate Cancer (1) Metastatic Castration-resistant Prostate Cancer, mCRPC (1) mCRPC (1) Metastatic Castration-Resistant Prostate Cancer Patients (1) Castration-resistant Prostate Cancer (1)

Modalities

small molecule (26), mixed (3), other (1)

Companies

Peter MacCallum Cancer Centre, Australia (2) Weill Medical College of Cornell University (2) Clarity Pharmaceuticals (2) C Ray Therapeutics (2) National Cancer Institute (NCI) (1) Chunjing Yu (1) Nova Therapeutics (1) Jinming Zhang (1) Eli Lilly (1) Xiaorong Sun (1) University Hospital, Basel, Switzerland (1) Fusion Pharmaceuticals (1) Lantheus Medical Imaging (1) M.D. Anderson Cancer Center (1) Columbia University (1) Sinotau Pharmaceutical Group (1) Norroy Bioscience (1) Inovio Pharmaceuticals (1) Curium US (1) First Affiliated Hospital of Fujian Medical University (1)

Related targets

FOLH1 (3) WT1 (1) HGNC (1) PSCA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.